Filing Flows › Comparisons › VVOS vs BTCY
Vivos Therapeutics vs Biotricity: VVOS and BTCY compared
Vivos Therapeutics is the larger company: $5.2M of revenue in its latest quarter (Q2 2026) against $4.3M for Biotricity (Q1 FY27). Vivos Therapeutics is growing faster (+35% against +10% a year earlier). Biotricity is more profitable, with an operating margin of 3.7% against -93.6%.
Where the money goes: VVOS and BTCY
Vivos Therapeutics (VVOS) · Q2 2026
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Biotricity (BTCY) · Q1 FY27
Biotricity, Q1 FY27: revenue $4.3M (+10% year over year), operating margin 3.7%, net loss $959K, operating cash flow $507K. The chart follows the revenue to costs, profit and cash.
| Vivos Therapeutics (VVOS) | Biotricity (BTCY) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 FY27 |
| Revenue | $5.2M | $4.3M |
| Revenue growth, Y/Y | +35% | +10% |
| Operating margin | -93.6% | 3.7% |
| Net earnings | −$5.5M | −$959K |
| Net margin | -107.2% | -22.4% |
| Operating cash flow | −$3.1M | $507K |
Where the revenue comes from
Vivos Therapeutics
- Service: $3.8M (74%)
- Product: $1.4M (26%)
Biotricity
- Technology Fees: $4.2M (97%)
- Device Sales: $111K (3%)
Questions
Which is bigger, Vivos Therapeutics or Biotricity?
Vivos Therapeutics is the larger company: $5.2M of revenue in its latest quarter (Q2 2026) against $4.3M for Biotricity (Q1 FY27).
Is Vivos Therapeutics or Biotricity growing faster?
Vivos Therapeutics is growing faster (+35% against +10% a year earlier).
Which is more profitable, Vivos Therapeutics or Biotricity?
Biotricity is more profitable, with an operating margin of 3.7% against -93.6%.
More: Vivos Therapeutics earnings · how Vivos Therapeutics makes money · Biotricity earnings · how Biotricity makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 19, 2026). Fiscal quarters can end on different dates. Not investment advice.